These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide. Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547 [TBL] [Abstract][Full Text] [Related]
23. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646 [TBL] [Abstract][Full Text] [Related]
24. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983 [TBL] [Abstract][Full Text] [Related]
25. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ; Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895 [TBL] [Abstract][Full Text] [Related]
26. Post-operative management of primary glioblastoma multiforme in patients over 60 years of age. Daróczi B; Szántó E; Tóth J; Barzó P; Bognár L; Bakó G; Szántó J; Mózes P; Hideghéty K Ideggyogy Sz; 2013 Nov; 66(11-12):391-8. PubMed ID: 24555238 [TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504 [TBL] [Abstract][Full Text] [Related]
28. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985 [TBL] [Abstract][Full Text] [Related]
29. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD; Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039 [TBL] [Abstract][Full Text] [Related]
30. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484 [TBL] [Abstract][Full Text] [Related]
31. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Combs SE; Gutwein S; Schulz-Ertner D; van Kampen M; Thilmann C; Edler L; Wannenmacher MM; Debus J Strahlenther Onkol; 2005 Jun; 181(6):372-7. PubMed ID: 15925979 [TBL] [Abstract][Full Text] [Related]
32. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602 [TBL] [Abstract][Full Text] [Related]
33. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015 [TBL] [Abstract][Full Text] [Related]
34. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Del Vecchio CA; Li G; Wong AJ Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662 [TBL] [Abstract][Full Text] [Related]
35. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196 [TBL] [Abstract][Full Text] [Related]
36. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709 [TBL] [Abstract][Full Text] [Related]
37. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329 [TBL] [Abstract][Full Text] [Related]
38. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883 [TBL] [Abstract][Full Text] [Related]
39. A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Rampling R; Peoples S; Mulholland PJ; James A; Al-Salihi O; Twelves CJ; McBain C; Jefferies S; Jackson A; Stewart W; Lindner J; Kutscher S; Hilf N; McGuigan L; Peters J; Hill K; Schoor O; Singh-Jasuja H; Halford SE; Ritchie JW Clin Cancer Res; 2016 Oct; 22(19):4776-4785. PubMed ID: 27225692 [TBL] [Abstract][Full Text] [Related]
40. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]